Anti-obesity medication/ja: Difference between revisions

@@ Line 226: / Line 226: @@
 ===未承認===
-<div lang="en" dir="ltr" class="mw-content-ltr">
 {| class="wikitable"
 |+
-!Medication Name
+!医薬品名
-!Trade name(s)
+!商品名
-!Mechanism of action
+!作用機序
-!Current FDA Status
+!現在のFDAステータス
-!placebo-adjusted percent bodyweight lost (highest dose studied)
+!プラセボ調整による体重減少率（最高用量試験）
 |-
-|[[Retatrutide]]
+|[[Retatrutide/ja]]
 |
-|GLP-1, [[GIP receptor|GIP]], and [[glucagon receptor]] triple agonist
+|GLP-1, [[GIP receptor/ja|GIP]], [[glucagon receptor/ja]]トリプルアゴニスト
-|In clinical trials
+|臨床試験中
-|24 percent in a Phase II trial
+|第II相試験では24％であった
 |-
-|[[Exenatide]]
+|[[Exenatide/ja]]
-|Byetta
+|バイエッタ
-|[[GLP-1 receptor agonist]]
+|[[GLP-1 receptor agonist/ja]]
-|Approved for type 2 diabetes
+|2型糖尿病治療薬として承認されている
 |{{convert|2.5|kg}}
 |-
-|[[Cetilistat]]
+|[[Cetilistat/ja]]
 |
-|Absorption inhibitor
+|吸収阻害剤
-|Not approved
+|未承認
 | {{convert|1.5|kg}}
 |-
-| [[Tesofensine]] (NS2330)
+| [[Tesofensine/ja]] (NS2330)
 |
-|[[Serotonin–norepinephrine–dopamine reuptake inhibitor]]
+|[[Serotonin–norepinephrine–dopamine reuptake inhibitor/ja]]
-|Not FDA approved
+|未承認
-|10.6 percent
+|10.6%
-</div>
 <div lang="en" dir="ltr" class="mw-content-ltr">